Sharenet Sites 
Sharenet Sites
The promotion of Ivermax 1% to treat COVID-19 on social media
Ascendis Health Limited
(Registration number 2008/005856/06)
(Incorporated in the Republic of South Africa)
Share code: ASC
ISIN: ZAE000185005
(“Ascendis Health” or “the Company”)
The promotion of Ivermax 1% to treat COVID-19 on social media
Ascendis Health has noted that a product within the Company’s Animal Health portfolio, Ivermax 1%, an antiparasitic
remedy for livestock, is being promoted on social media as a potential treatment for Covid-19 in humans.
In line with the General Principles of the JSE Listings Requirements to ensure that full, equal and timeous public
disclosure is made to all shareholders of Ascendis Health and the general public at large regarding the activities of the
Company that may be price sensitive, Ascendis Health would hereby like to distance itself from these reports and urges
the public to make informed and safe choices regarding their health and only utilise products that have been
scientifically proven.
Although Ivermax contains Ivermectin, which has recently made headlines as a so-called “miracle cure” for Covid-19,
the Company would like to state that Ivermax is not indicated or approved by Ascendis Health for use in humans.
Whilst Ivermectin is being promoted as an affordable and effective antidote to Covid-19 the South African Health
Products Authority (SAHPRA), has not authorised it as a treatment for Covid-19.
On 22 December 2020, SAHPRA released a statement that “Ivermectin is not indicated nor approved by SAHPRA for
use in humans. There is no confirmatory data on Ivermectin available as yet for its use in the management of Covid-
19 infections. In terms of safety and efficacy, there is no evidence to support the use of Ivermectin and we do not have
any clinical trial evidence to justify its use.”
Ascendis Health prioritises the quality, safety and efficacy of our products, and the health and well-being of South
Africans. Ascendis urges the public not to use Ivermax to treat the pandemic.
15 January 2021
Bryanston
Sponsor
Questco Corporate Advisory Proprietary Limited
Date: 15-01-2021 03:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
